Orbis's 5% Stake Trim in Genmab Signals Closing of the Growth-Valuation Gap

The story begins with a clear signal. In late September 2025, Orbis Investment Management Limited disclosed that it had built a 5.03% stake in Genmab, becoming a major shareholder. This wasn't a casual position; it was a statement of conviction, likely made as the company was riding a wave of strong performance. The market had priced in that growth, as evidenced by the stock's 51.41% surge in 2025.

Fast forward to early March 2026, and the picture shifts. Orbis reported reducing its stake to 4.99%. That single basis point reduction is the central puzzle. It suggests a tactical exit, a decision to take some money off the table. The key question is why. The most straightforward interpretation is that Orbis's initial 5% entry signaled confidence in Genmab's long-term trajectory. Its subsequent reduction to just under 5% implies that confidence has cooled on the near term. The market's strong growth expectations, already reflected in the stock's 2025 rally, may now be fully priced in. With the stock falling 7.64% in 2026 despite that earlier beat, the expectation gap has become a reality gap. Orbis's move reads as a bet that the near-term catalysts needed to drive the stock materially higher are not sufficient to justify holding the full position.

The Expectation Gap: Growth vs. Guidance and Valuation

The market's consensus on Genmab is clear: it's a growth story priced in. The company's headline numbers support that view. Total revenue grew 19% in 2025 to $3.7 billion, driven by a 54% surge in proprietary medicine sales. The pipeline is active, with new Phase 3 trials and recent approvals. This robust growth fuels a Buy rating with a $43.00 price target from analysts. In other words, the market is paying for the story of continued expansion from products like Abkinley and the enduring royalty engine of Darzalex.

The expectation gap, however, lies in profitability. While revenue climbs, operating margins have been on a declining trend over the past five years, averaging a -10.4% annual decrease. This is the disconnect. The market is pricing in strong top-line growth but not yet a sustained margin turnaround. For a biotech, translating sales into bottom-line efficiency is the ultimate validation. Until that happens, the valuation premium may be vulnerable.

Orbis's tactical exit at a 4.99% stake suggests the investor sees this gap as a near-term ceiling. The stock's 51.41% surge in 2025 likely reflected optimism for this growth trajectory. Its subsequent pullback in 2026, despite the strong revenue beat, indicates that the market is now weighing the margin pressure. Orbis's move reads as a bet that the current price already reflects the best-case growth scenario, leaving little room for upside if the company cannot demonstrate a clear path to improved profitability. The expectation gap is between the market's confidence in Genmab's sales engine and its skepticism about its cost structure. Until the latter closes, the former may struggle to drive the stock materially higher.

Catalysts and Risks: Testing the Thesis

The upcoming months will test whether Orbis's tactical exit was a savvy move or a premature retreat. The company's path hinges on two intertwined catalysts: clearing regulatory hurdles for its pipeline and demonstrating that its ambitious growth can translate into improved profitability.

The most immediate overhang is the Phase 3 EPCOR trial for Abkinley in diffuse large B-cell lymphoma. While the trial met its primary endpoint for progression-free survival, it missed statistical significance for overall survival. This has triggered ongoing discussions with regulatory authorities to address trial biases, including the impact of subsequent therapies and the pandemic. The unresolved regulatory path creates near-term uncertainty. A clean approval would validate the drug's efficacy and support the growth thesis. Any delay or requirement for additional data would be a tangible headwind, potentially weighing on the stock as the market re-evaluates the near-term sales timeline.

On the execution front, Genmab must show it can leverage its expanded pipeline. The company strategically expanded throughout the year, highlighted by the acquisition of ProfoundBio and its late-stage asset, Rina-S. The key will be the results from its three new Phase 3 trials. Positive data here would reinforce the growth narrative and justify the premium valuation. Conversely, setbacks would widen the expectation gap, showing that pipeline execution is not a sure thing.

The primary risk, however, remains the profitability disconnect. The market is paying for the 19% revenue growth in 2025 and the $468 million in Abkinley sales, but it is not yet pricing in a margin turnaround. The company's operating margins have been on a declining trend over the past five years. If revenue growth slows before operating margins improve, the gap between headline growth and bottom-line reality will widen. This is the scenario that would make Orbis's exit look prescient: a stock that has already priced in strong sales but faces mounting pressure on its cost structure. The coming catalysts will reveal whether Genmab can close that gap or if the expectation gap has become a permanent chasm.